Impact of PSMA PET on Prostate Cancer Management

By sjmartinez • January 26, 2024

Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, Raman SS, Calais J, Boutros PC, Reiter RE. Impact of PSMA PET on Prostate Cancer Management. Curr Treat Options Oncol. 2024 Jan 25. doi: 10.1007/s11864-024-01181-9. Epub ahead of print. PMID: 38270802.

Tags: Clinical decision-making, drug therapy, Hematology/Oncology, Neoplasm staging, Positron-emission tomography, prognosis, Prostatic neoplasms, Publications, Radiotherapy, Surgery, Theranostic nanomedicine, Veterans Administration

Related Posts

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J,[...]

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer[...]

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]